Do analysts recommend AADI or CCCC?

C4 Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 98.72%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 C4 Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Do analysts prefer AADI or RZLT?

Rezolute has a consensus target price of $8.75, indicating a potential upside of 118.75%. Given Rezolute's stronger consensus rating and higher probable upside, analysts clearly believe Rezolute is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Rezolute 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Do analysts recommend AADI or EPRX?

Eupraxia Pharmaceuticals has a consensus price target of $18.33, indicating a potential upside of 203.53%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Eupraxia Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89

Do analysts recommend AADI or AUTL?

Autolus Therapeutics has a consensus target price of $8.75, indicating a potential upside of 460.90%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Autolus Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 2.89

Do analysts rate AADI or IPSC?

Century Therapeutics has a consensus target price of $4.75, indicating a potential upside of 111.11%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Century Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Aadi Bioscience (AADI) Competitors

$4.16 +0.10 (+2.46%)

As of 06/12/2026

Compare

AADI vs. CCCC, RZLT, EPRX, AUTL, and IPSC

Should you buy Aadi Bioscience stock or one of its competitors? MarketBeat compares Aadi Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aadi Bioscience include C4 Therapeutics (CCCC), Rezolute (RZLT), Eupraxia Pharmaceuticals (EPRX), Autolus Therapeutics (AUTL), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry.

How does Aadi Bioscience compare to C4 Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and C4 Therapeutics (NASDAQ:CCCC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, C4 Therapeutics has a beta of 2.91, meaning that its share price is 191% more volatile than the broader market.

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 78.8% of C4 Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 5.6% of C4 Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aadi Bioscience has a net margin of -246.06% compared to C4 Therapeutics' net margin of -297.76%. C4 Therapeutics' return on equity of -50.68% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
C4 Therapeutics	-297.76%	-50.68%	-33.22%

Aadi Bioscience has higher earnings, but lower revenue than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A
C4 Therapeutics	$35.95M	12.00	-$104.99M	-$1.19	N/A

C4 Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 98.72%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
C4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, C4 Therapeutics had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for C4 Therapeutics and 0 mentions for Aadi Bioscience. C4 Therapeutics' average media sentiment score of 0.24 beat Aadi Bioscience's score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
C4 Therapeutics	Neutral

Summary

C4 Therapeutics beats Aadi Bioscience on 12 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Rezolute?

Aadi Bioscience (NASDAQ:AADI) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Rezolute had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Rezolute and 0 mentions for Aadi Bioscience. Rezolute's average media sentiment score of 0.38 beat Aadi Bioscience's score of 0.00 indicating that Rezolute is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Rezolute	Neutral

Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Aadi Bioscience has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Comparatively, 14.8% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Rezolute has a consensus target price of $8.75, indicating a potential upside of 118.75%. Given Rezolute's stronger consensus rating and higher probable upside, analysts clearly believe Rezolute is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Rezolute	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Rezolute has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Rezolute's return on equity of -58.82% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Rezolute	N/A	-58.82%	-54.48%

Summary

Rezolute beats Aadi Bioscience on 10 of the 14 factors compared between the two stocks.

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Aadi Bioscience (NASDAQ:AADI) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

52.1% of Aadi Bioscience shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Eupraxia Pharmaceuticals had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Eupraxia Pharmaceuticals and 0 mentions for Aadi Bioscience. Eupraxia Pharmaceuticals' average media sentiment score of 0.62 beat Aadi Bioscience's score of 0.00 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Eupraxia Pharmaceuticals	Positive

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Aadi Bioscience. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.05	N/A

Eupraxia Pharmaceuticals has a consensus price target of $18.33, indicating a potential upside of 203.53%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Eupraxia Pharmaceuticals	N/A	-87.56%	-51.20%

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Aadi Bioscience on 11 of the 16 factors compared between the two stocks.

How does Aadi Bioscience compare to Autolus Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Aadi Bioscience has a net margin of -246.06% compared to Autolus Therapeutics' net margin of -311.98%. Aadi Bioscience's return on equity of -71.87% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

Autolus Therapeutics has a consensus target price of $8.75, indicating a potential upside of 460.90%. Given Autolus Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Autolus Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

In the previous week, Autolus Therapeutics had 4 more articles in the media than Aadi Bioscience. MarketBeat recorded 4 mentions for Autolus Therapeutics and 0 mentions for Aadi Bioscience. Autolus Therapeutics' average media sentiment score of 0.30 beat Aadi Bioscience's score of 0.00 indicating that Autolus Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Autolus Therapeutics	Neutral

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market.

Aadi Bioscience has higher earnings, but lower revenue than Autolus Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A
Autolus Therapeutics	$75.39M	5.51	-$287.53M	-$1.09	N/A

Summary

Autolus Therapeutics beats Aadi Bioscience on 13 of the 17 factors compared between the two stocks.

How does Aadi Bioscience compare to Century Therapeutics?

Aadi Bioscience (NASDAQ:AADI) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Century Therapeutics has lower revenue, but higher earnings than Aadi Bioscience. Century Therapeutics is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.10	-$65.76M	-$2.35	N/A
Century Therapeutics	N/A	N/A	-$9.58M	-$1.14	N/A

Century Therapeutics has a consensus target price of $4.75, indicating a potential upside of 111.11%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Century Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Century Therapeutics' return on equity of -49.89% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Century Therapeutics	N/A	-49.89%	-37.42%

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 2.4% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Century Therapeutics had 6 more articles in the media than Aadi Bioscience. MarketBeat recorded 6 mentions for Century Therapeutics and 0 mentions for Aadi Bioscience. Century Therapeutics' average media sentiment score of 0.26 beat Aadi Bioscience's score of 0.00 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Century Therapeutics	Neutral

Aadi Bioscience has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Summary

Century Therapeutics beats Aadi Bioscience on 11 of the 15 factors compared between the two stocks.

Get Aadi Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AADI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AADI vs. The Competition

Export

Metric	Aadi Bioscience	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$102.74M	$979.54M	$6.52B	$12.05B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	-1.82	1.45	24.00	24.42
Price / Sales	4.10	120.49	514.36	111.24
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	0.97	7.85	10.54	6.82
Net Income	-$65.76M	-$4.88M	$3.57B	$337.56M
7 Day Performance	0.24%	0.64%	0.60%	1.17%
1 Month Performance	-18.43%	-0.16%	1.56%	3.16%
1 Year Performance	112.24%	47.51%	25.42%	30.58%

Aadi Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AADI Aadi Bioscience	N/A	$4.16 +2.5%	N/A	+112.2%	$102.74M	$25.07M	N/A	40
CCCC C4 Therapeutics	1.8388 of 5 stars	$3.58 -0.3%	$7.75 +116.5%	+132.1%	$396.94M	$35.95M	N/A	150	Positive News
RZLT Rezolute	3.3616 of 5 stars	$3.90 -4.4%	$8.75 +124.4%	-4.8%	$392.87M	N/A	N/A	40	Analyst Downgrade
EPRX Eupraxia Pharmaceuticals	2.2375 of 5 stars	$5.96 -0.5%	$18.33 +207.6%	+56.5%	$389.46M	N/A	N/A	29	News Coverage Positive News
AUTL Autolus Therapeutics	3.7861 of 5 stars	$1.46 flat	$8.75 +499.3%	-26.4%	$388.59M	$75.39M	N/A	330	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AADI) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aadi Bioscience (AADI) Competitors

AADI vs. CCCC, RZLT, EPRX, AUTL, and IPSC

How does Aadi Bioscience compare to C4 Therapeutics?

Summary

How does Aadi Bioscience compare to Rezolute?

Summary

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Summary

How does Aadi Bioscience compare to Autolus Therapeutics?

Summary

How does Aadi Bioscience compare to Century Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aadi Bioscience (AADI) Competitors

AADI vs. CCCC, RZLT, EPRX, AUTL, and IPSC

How does Aadi Bioscience compare to C4 Therapeutics?

Which has more volatility and risk, AADI or CCCC?

Do institutionals & insiders have more ownership in AADI or CCCC?

Is AADI or CCCC more profitable?

Which has higher valuation & earnings, AADI or CCCC?

Do analysts recommend AADI or CCCC?

Does the media prefer AADI or CCCC?

Summary

How does Aadi Bioscience compare to Rezolute?

Does the media refer more to AADI or RZLT?

Which has more volatility and risk, AADI or RZLT?

Which has preferable earnings & valuation, AADI or RZLT?

Do institutionals and insiders have more ownership in AADI or RZLT?

Do analysts prefer AADI or RZLT?

Is AADI or RZLT more profitable?

Summary

How does Aadi Bioscience compare to Eupraxia Pharmaceuticals?

Do institutionals & insiders believe in AADI or EPRX?

Does the media refer more to AADI or EPRX?

Which has preferable valuation and earnings, AADI or EPRX?

Do analysts recommend AADI or EPRX?

Is AADI or EPRX more profitable?

Which has more risk and volatility, AADI or EPRX?

Summary

How does Aadi Bioscience compare to Autolus Therapeutics?

Is AADI or AUTL more profitable?

Do analysts recommend AADI or AUTL?

Does the media refer more to AADI or AUTL?

Do insiders & institutionals believe in AADI or AUTL?

Which has more risk & volatility, AADI or AUTL?

Which has stronger earnings & valuation, AADI or AUTL?

Summary

How does Aadi Bioscience compare to Century Therapeutics?

Which has stronger valuation and earnings, AADI or IPSC?

Do analysts rate AADI or IPSC?

Is AADI or IPSC more profitable?

Do insiders and institutionals believe in AADI or IPSC?

Does the media refer more to AADI or IPSC?

Which has more volatility and risk, AADI or IPSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AADI vs. The Competition

Aadi Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools